1. Fujita M, Sasayama S, Ohno A, et al. Importance of angina for development of collateral circulation. Br Heart J. 1987;57(2):139-43. doi:10.1136/hrt.57.2.139.
2. Zimarino M, D’Andreamatteo M, Waksman R, et al. The dynamics of the coronary collateral circulation. Nat Rev Cardiol. 2014;11(4):191-7. doi:10.1038/nrcardio.2013.207.
3. Di Mario C, Werner GS, Sianos G, et al. European perspective in the recanalization of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. EuroIntervention. 2007;3(1):30-43.
4. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468-81. doi:10.1016/j.cmet.2008.10.011.
5. Butler AA, Havel PJ. Adropin and insulin resistance: Integration of endocrine, circadian, and stress signals regulating glucose metabolism. Obesity (Silver Spring). 2021;29(11):1799-801. doi:10.1002/oby.23249.
6. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122(11 Suppl): S185-92. doi:10.1161/CIRCULATIONAHA.109.931782.
7. Murphy JG (ed.). Mayo Clinic Cardiology Review. Lippincott Williams & Wilkins 2000; 1381.
8. Bashore TM, Bates ER, Berger PB, et al. American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37(8):2170-214. doi:10.1016/S0735-1097(01)01346-8.
9. Morino Y, Abe M, Morimoto T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv. 2011;4(2):213-21. doi:10.1016/j.jcin.2010.09.024.
10. Christopoulos G, Wyman RM, Alaswad K, et al. Clinical Utility of the Japan-Chronic Total Occlusion Score in Coronary Chronic Total Occlusion Interventions: Results from a Multicenter Registry. Circ Cardiovasc Interv. 2015;8(7):e002171. doi:10.1161/CIRCINTERVENTIONS.114.002171.
11. Bufe A, Haltern G, Dinh W, et al. Recanalization of coronary chronic total occlusions with new techniques including the retrograde approach via collaterals. Neth Heart J. 2011;19(4):162-7. doi:10.1007/s12471-011-0091-7.
12. Chen SL, Ye F, Zhang JJ, et al. Clinical outcomes of percutaneous coronary intervention for chronic total occlusion lesions in remote hospitals without on-site surgical support. Chin Med J (Engl.). 2009;122(19):2278-85.
13. Akkaya H, Güntürk EE, Akkaya F, et al. Assessment of the Relationship Between the Adropin Levels and the Coronary Collateral Circulation in Patients wıth Chronic Coronary Syndrome. Arq Bras Cardiol. 2022;119(3):402-10. English, Portuguese. doi:10.36660/abc.20210573.
14. Vural A, Kurt D, Karagöz A, et al. The Relationship Between Coronary Collateral Circulation and Serum Adropin Levels. Cureus. 2023;15(2):e35166. doi:10.7759/cureus.35166.
15. Meier P, Zbinden R, Togni M, et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol. 2007;49(1):15-20. doi:10.1016/j.jacc.2006.08.043.
16. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128-35. doi:10.1038/nm0202-128.
17. Topuz M, Celik A, Aslantas T, et al. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in individuals with type 2 diabetes mellitus. J Investig Med. 2013;61(8):1161-4. doi:10.2310/JIM.0000000000000003.